Demonstrates effective psoriasis therapy using platinum nanoclusters, suggesting potential for improved management without major side effects.
Psoriasis is a chronic inflammatory skin disease that affects millions worldwide. Current treatments are often limited by side effects and high relapse rates. This study introduces an ultrasmall platinum-nanocluster-based artificial enzyme (Pt NE) for effective psoriasis therapy and relapse prevention. Pt NEs exhibit multienzyme mimetic activities─superoxide dismutase, catalase, and glutathione peroxidase-like─with an overall antioxidant capacity 5-fold greater than Au or Cu analogues. Their superior skin penetration (69.93% and 14.27% higher than Au and Cu NEs, respectively) enables efficient reactive oxygen species scavenging and modulation of the inflammatory microenvironment. In vivo, Pt NEs achieve complete psoriatic symptom remission, comparable to a commercial calcipotriol/betamethasone ointment but without steroid-associated adverse effects. Mechanistically, Pt NEs modulate immunity by downregulating pro-inflammatory genes and upregulating genes related to proliferation inhibition and apoptosis. Excellent biocompatibility was observed, with no detectable organ damage or systemic toxicity. This work proposes a safe, effective, and cost-efficient nanotherapeutic strategy with strong potential for clinical translation in psoriasis management.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: